BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28450405)

  • 21. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
    Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
    Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adrenal malignant melanoma masquerading as a pheochromocytoma in a patient with a history of a multifocal papillary and medullary thyroid carcinoma.
    Barmpari ME; Savvidis C; Dede AD; Markogiannakis H; Dikoglou C; Xekouki P; Stratakis CA; Andreas M; Malaktari-Skarantavou S
    Hormones (Athens); 2016 Apr; 15(2):283-290. PubMed ID: 27376430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for vigilance: false-negative screening for adenylosuccinate lyase deficiency caused by deribosylation of urinary biomarkers.
    Krijt J; Skopova V; Adamkova V; Cermakova R; Jurecka A; Kmoch S; Zikanova M
    Clin Biochem; 2013 Dec; 46(18):1899-901. PubMed ID: 24183879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
    Sturgeon C; Shen WT; Clark OH; Duh QY; Kebebew E
    J Am Coll Surg; 2006 Mar; 202(3):423-30. PubMed ID: 16500246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolomic profile of the adrenal gland: from physiology to pathological conditions.
    Imperiale A; Elbayed K; Moussallieh FM; Reix N; Piotto M; Bellocq JP; Goichot B; Bachellier P; Namer IJ
    Endocr Relat Cancer; 2013 Oct; 20(5):705-16. PubMed ID: 23921203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors.
    Ozimek A; Diebold J; Linke R; Heyn J; Hallfeldt K; Mussack T
    Endocr J; 2008 Aug; 55(4):625-38. PubMed ID: 18490838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Interesting Case of Hepatic Adrenocortical Carcinoma.
    Permana H; Darmawan G; Ritonga E; Kusumawati M; Miftahurachman M; Soetedjo NN
    Acta Med Indones; 2018 Jul; 50(3):257-259. PubMed ID: 30333277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors.
    Ma FH; Qiang JW; Cai SQ; Zhao SH; Zhang GF; Rao YM
    AJR Am J Roentgenol; 2015 Jun; 204(6):W724-30. PubMed ID: 26001263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center.
    Luton JP; Martinez M; Coste J; Bertherat J
    Eur J Endocrinol; 2000 Jul; 143(1):111-7. PubMed ID: 10870039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Adrenal Gland: Report of a Rare Case Posing Diagnostic Challenge with the Role of Immunohistochemistry in the Diagnosis.
    Pant L; Kalita D; Chopra R; Das A; Jain G
    Endocr Pathol; 2015 May; 26(2):129-34. PubMed ID: 25724713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone?
    Song JH; Grand DJ; Beland MD; Chang KJ; Machan JT; Mayo-Smith WW
    AJR Am J Roentgenol; 2013 Dec; 201(6):1248-53. PubMed ID: 24261363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary metabolomic profiling for noninvasive diagnosis of acute T cell-mediated rejection after kidney transplantation.
    Kim SY; Kim BK; Gwon MR; Seong SJ; Ohk B; Kang WY; Lee HW; Jung HY; Cho JH; Chung BH; Lee SH; Kim YH; Yoon YR; Kim CD; Cho S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1118-1119():157-163. PubMed ID: 31054449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study.
    Haznadar M; Cai Q; Krausz KW; Bowman ED; Margono E; Noro R; Thompson MD; Mathé EA; Munro HM; Steinwandel MD; Gonzalez FJ; Blot WJ; Harris CC
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):978-86. PubMed ID: 27013655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis.
    Ozsari L; Kutahyalioglu M; Elsayes KM; Vicens RA; Sircar K; Jazaerly T; Waguespack SG; Busaidy NL; Cabanillas ME; Dadu R; Hu MI; Vassilopoulou-Sellin R; Jimenez C; Lee JE; Habra MA
    Endocrine; 2016 Feb; 51(2):351-9. PubMed ID: 26206754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of incidentally discovered adrenal masses and risk of malignancy.
    Favia G; Lumachi F; Basso S; D'Amico DF
    Surgery; 2000 Dec; 128(6):918-24. PubMed ID: 11114624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of adrenocortical tumors by
    Paladino NC; Guérin C; Lowery A; Attard A; Essamet W; Slotema E; Morange I; Castinetti F; Brue T; Loundou A; Taïeb D; Sebag F
    Surg Oncol; 2018 Jun; 27(2):231-235. PubMed ID: 29937176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result.
    Ito T; Imai T; Kikumori T; Shibata A; Horiba T; Kobayashi H; Sawaki M; Watanabe R; Nakao A; Kiuchi T
    Surg Today; 2006; 36(11):961-5. PubMed ID: 17072715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.
    Crowley MJ; Scognamiglio T; Liu YF; Kleiman DA; Beninato T; Aronova A; Liu H; Jhanwar YS; Molina A; Tagawa ST; Bander NH; Zarnegar R; Elemento O; Fahey TJ
    J Clin Endocrinol Metab; 2016 Mar; 101(3):981-7. PubMed ID: 26771706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenal incidentalomas: risk of adrenocortical carcinoma and clinical outcomes.
    O'Neill CJ; Spence A; Logan B; Suliburk JW; Soon PS; Learoyd DL; Sidhu SB; Sywak MS
    J Surg Oncol; 2010 Oct; 102(5):450-3. PubMed ID: 20734420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.